Dingdan Lu

Anlotinib combined with almonertinib reverses almonertinib resistance in lung adenocarcinoma by inhibiting the c-MET/PI3K/AKT pathway

Almonertinib resistance poses a major challenge in treating lung adenocarcinoma (LUAD) with epidermal growth factor receptor (EGFR) mutations. Research indicates that the c-MET/PI3K/AKT signaling pathway and epithelial-mesenchymal transition (EMT) are closely associated with resi...